Gene profiling in active dermatitis lesions strengthens the diagnosis of allergic contact dermatitis - 11/04/24
, Audrey Nosbaum, MD, PhD a, c, Amandine Mosnier, MSc a, Vanina Lenief, MSc a, Samuel Salque, MSc a, Marie Pichot, MSc a, Lea Maheux, MSc a, Lea Bertolotti, MD c, Florence Hacard, MD c, Celine Graveriau, MD d, Pascale Zukervar, MD d, Anne-Laure Breton Guitarian, MD d, Fanny Boisleve, PharmD, PhD e, Michelle Elbaz, PharmD e, Jean-François Nicolas, MD, PhD a, c, Marc Vocanson, PhD a, ⁎ Abstract |
Background |
Distinguishing between allergic and nonallergic forms of Contact Dermatitis (CD) is challenging and requires investigations based on patch-testing. Early detection of allergy biomarkers in active CD lesions could refine and simplify the management of CD patients.
Objective |
To characterize the molecular signatures of active CD lesions.
Methods |
We studied the expression of 12 allergy biomarkers by qRT-PCR in active lesions of 38 CD patients. Allergic CD (ACD) was diagnosed based on patch test (PT) results and exposure assessment. Molecular signatures of active lesions, as well as positive PT reactions, were compared with those of reference chemical allergens and irritants.
Results |
Nineteen of the 38 CD patients reacted positively upon patch-testing and exposure assessment confirmed ACD diagnosis for 17 of them. Gene profiling of active CD lesions revealed 2 distinct molecular patterns: patients harboring signatures similar to reference allergens (n = 23) or irritants (n = 15). Among the 23 patients with an “allergy signature,” we found the 17 patients with confirmed ACD, while no culprit allergen was identified for the 6 other patients. Interestingly, the 15 patients without biomarker induction had negative PT, suggesting that they developed nonallergic CD reactions.
Conclusion |
Molecular signatures from active skin lesions may help to stratify CD patients and predict those suffering from ACD.
Le texte complet de cet article est disponible en PDF.Key words : allergic contact dermatitis, biomarkers, irritant contact dermatitis, molecular signature, point of care diagnosis, transcriptomic profiling
Abbreviations used : ACD, CD, CXCL10, EBS, Fc, GPR183, GZMB, HLA-DRA, ICD, IFNG, IGFL3, IL-15, PCA, PLEK, PT, qRT-PCR
Plan
| Funding sources: Grant was obtained from Chanel (Neuilly-sur-Seine, France) to help the realization of this work. |
|
| Patient consent: Consent for the publication of recognizable patient photographs or other identifiable material was obtained by the authors and included at the time of article submission to the journal stating that all patients gave consent with the understanding that this information may be publicly available. |
|
| IRB approval status: n°23-5132. |
Vol 90 - N° 5
P. 953-962 - mai 2024 Retour au numéro
Article précédent
- Efficacy and safety of crisaborole ointment, 2%, in participants aged ≥45 years with stasis dermatitis: Results from a fully decentralized, randomized, proof-of-concept phase 2a study
- Jonathan I. Silverberg, Robert S. Kirsner, David J. Margolis, Michael Tharp, Daniela E. Myers, Karen Annis, Daniela Graham, Chuanbo Zang, Bonnie L. Vlahos, Paul Sanders
- Loss in life expectancy in patients with stage II-III cutaneous melanoma in Sweden: A population-based cohort study
- Sofi Vikström, Elisavet Syriopoulou, Therese M.-L. Andersson, Hanna Eriksson
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?